- Home
- COYA vs SGMO Comparison
COYA vs SGMO Comparison
Compare COYA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- SGMO
- Stock Information
- Founded
- COYA 2020
- SGMO 1995
- Country
- COYA United States
- SGMO United States
- Employees
- COYA N/A
- SGMO N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COYA Health Care
- SGMO Health Care
- Exchange
- COYA Nasdaq
- SGMO Nasdaq
- Market Cap
- COYA 107.0M
- SGMO 122.8M
- IPO Year
- COYA 2022
- SGMO 2000
- Fundamental
- Price
- COYA $6.28
- SGMO $0.68
- Analyst Decision
- COYA Strong Buy
- SGMO Strong Buy
- Analyst Count
- COYA 5
- SGMO 7
- Target Price
- COYA $16.20
- SGMO $5.29
- AVG Volume (30 Days)
- COYA 81.7K
- SGMO 5.6M
- Earning Date
- COYA 11-05-2025
- SGMO 11-11-2025
- Dividend Yield
- COYA N/A
- SGMO N/A
- EPS Growth
- COYA N/A
- SGMO N/A
- EPS
- COYA N/A
- SGMO N/A
- Revenue
- COYA $423,452.00
- SGMO $81,706,000.00
- Revenue This Year
- COYA $40.80
- SGMO $28.47
- Revenue Next Year
- COYA N/A
- SGMO N/A
- P/E Ratio
- COYA N/A
- SGMO N/A
- Revenue Growth
- COYA N/A
- SGMO 565.52
- 52 Week Low
- COYA $4.65
- SGMO $0.41
- 52 Week High
- COYA $10.24
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- COYA 58.44
- SGMO 62.57
- Support Level
- COYA $5.10
- SGMO $0.65
- Resistance Level
- COYA $6.70
- SGMO $0.73
- Average True Range (ATR)
- COYA 0.30
- SGMO 0.05
- MACD
- COYA 0.12
- SGMO 0.01
- Stochastic Oscillator
- COYA 81.23
- SGMO 60.91
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.